Summary of Study ST000527

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000387. The data can be accessed directly via it's Project DOI: 10.21228/M81G7P This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000527
Study TitleEffects of Curcumin Supplementation on the Acylcarnitine Concentration of Older Adults: Relation to Vascular Function (part 4)
Study SummaryPerform acylcarnitine concentrations metabolite analysis related to nitric oxide biology, oxidative stress and inflammation in plasma before and after 12 weeks of oral curcumin (2000 mg/d) or placebo (double-blind, randomized) in men and women aged 45-79 years who are free from clinical cardiovascular disease.
Mayo Clinic
Last NameSeals
First NameDouglas
AddressDepartment of Integrative Physiology University of Colorado Boulder, CO 80309
Submit Date2016-12-14
Analysis Type DetailLC-MS
Release Date2018-12-11
Release Version1
Douglas Seals Douglas Seals application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000387
Project DOI:doi: 10.21228/M81G7P
Project Title:Mayo Metabolomics Pilot and Feasibility Award: Effects of Curcumin Supplementation on the Plasma Metabolome of Older Adults: Relation to Vascular Function
Project Summary:Age is the major risk factor for cardiovascular diseases (CVD). Two key contributors to the increased risk of CVD in middle-aged and older (MA/O) adults are stiffening of the large elastic arteries and the development of vascular endothelial dysfunction, indicated by impaired nitric oxide (NO)-induced endothelium-dependent dilation (EDD). The mechanisms by which aging causes arterial dysfunction are incompletely understood, but involve reductions in NO bioavailability associated with the development of oxidative stress and inflammation. Thus, establishing novel strategies to reduce arterial stiffness and increase vascular endothelial function in MA/O adults by increasing NO bioavailability and reducing oxidative stress and inflammation are a high biomedical research priority. Curcumin is a naturally occurring phenol found in the Indian spice turmeric that improves physiological function in animal models of age-related diseases and is a promising nutraceutical for intervention for promoting healthy aging. Our preclinical results indicate that chow supplemented with curcumin reduces aortic pulse wave velocity (PWV), the most common and clinically important measure of large elastic artery stiffness, restores NO-mediated EDD and reduces arterial oxidative stress and inflammation in old C57/BL6 mice. Preliminary data from our recently funded NIH R21 pilot grant indicate that curcumin supplementation improves vascular function in humans. It is possible that changes in the circulating (plasma) metabolome with oral curcumin supplementation will provide insight into novel metabolic mechanisms by which curcumin may improve vascular function. The goal of this project is to identify key metabolic pathways that change with oral curcumin supplementation and to relate those changes with improvements in vascular function in MA/O adults with initial endothelial dysfunction. Metabolomic analysis of plasma samples at baseline also may produce unique molecular signatures that predict responsiveness (changes in vascular function) to curcumin supplementation among individuals.
Institute:Mayo Clinic
Last Name:Seals
First Name:Douglas
Address:Department of Integrative Physiology University of Colorado Boulder, CO 80309


Subject ID:SU000549
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human


Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id group Time point
SA027685ms5643-29Old-Curcumin Post
SA027686ms5644-15Old-Curcumin Post
SA027687ms5644-22Old-Curcumin Post
SA027688ms5643-15Old-Curcumin Post
SA027689ms5643-18Old-Curcumin Post
SA027690ms5643-27Old-Curcumin Post
SA027691ms5643-20Old-Curcumin Post
SA027692ms5643-22Old-Curcumin Post
SA027693ms5644-27Old-Curcumin Post
SA027694ms5644-29Old-Curcumin Post
SA027695ms5643-3Old-Curcumin Post
SA027696ms5644-3Old-Curcumin Post
SA027697ms5644-25Old-Curcumin Post
SA027698ms5644-5Old-Curcumin Post
SA027699ms5643-10Old-Curcumin Post
SA027700ms5643-8Old-Curcumin Post
SA027701ms5643-26Old-Curcumin Pre
SA027702ms5644-14Old-Curcumin Pre
SA027703ms5644-4Old-Curcumin Pre
SA027704ms5643-28Old-Curcumin Pre
SA027705ms5643-19Old-Curcumin Pre
SA027706ms5643-9Old-Curcumin Pre
SA027707ms5644-24Old-Curcumin Pre
SA027708ms5643-7Old-Curcumin Pre
SA027709ms5644-26Old-Curcumin Pre
SA027710ms5643-2Old-Curcumin Pre
SA027711ms5643-14Old-Curcumin Pre
SA027712ms5644-28Old-Curcumin Pre
SA027713ms5643-21Old-Curcumin Pre
SA027714ms5644-2Old-Curcumin Pre
SA027715ms5643-17Old-Curcumin Pre
SA027716ms5644-21Old-Curcumin Pre
SA027717ms5644-18Old-Placebo Post
SA027718ms5644-10Old-Placebo Post
SA027719ms5644-13Old-Placebo Post
SA027720ms5644-20Old-Placebo Post
SA027721ms5644-8Old-Placebo Post
SA027722ms5643-32Old-Placebo Post
SA027723ms5643-34Old-Placebo Post
SA027724ms5644-32Old-Placebo Post
SA027725ms5644-34Old-Placebo Post
SA027726ms5643-25Old-Placebo Post
SA027727ms5643-13Old-Placebo Post
SA027728ms5644-36Old-Placebo Post
SA027729ms5643-5Old-Placebo Post
SA027730ms5643-36Old-Placebo Post
SA027731ms5643-4Old-Placebo Pre
SA027732ms5643-24Old-Placebo Pre
SA027733ms5644-19Old-Placebo Pre
SA027734ms5643-12Old-Placebo Pre
SA027735ms5644-35Old-Placebo Pre
SA027736ms5644-17Old-Placebo Pre
SA027737ms5643-31Old-Placebo Pre
SA027738ms5644-7Old-Placebo Pre
SA027739ms5644-31Old-Placebo Pre
SA027740ms5644-33Old-Placebo Pre
SA027741ms5643-33Old-Placebo Pre
SA027742ms5643-35Old-Placebo Pre
SA027743ms5644-9Old-Placebo Pre
SA027744ms5644-12Old-Placebo Pre
SA027745ms5644-37young Baseline
SA027746ms5644-30young Baseline
SA027747ms5644-1young Baseline
SA027748ms5643-23young Baseline
SA027749ms5643-16young Baseline
SA027750ms5643-11young Baseline
SA027751ms5643-6young Baseline
SA027752ms5643-30young Baseline
SA027753ms5643-37young Baseline
SA027754ms5644-16young Baseline
SA027755ms5644-11young Baseline
SA027756ms5644-6young Baseline
SA027757ms5643-1young Baseline
SA027758ms5644-23young Baseline
Showing results 1 to 74 of 74


Collection ID:CO000543
Collection Summary:Healthy men & women aged 45-79 without clinical CVD, but with below normal baseline endothelial dysfunction (FMDBA < 7%).
Sample Type:Blood


Treatment ID:TR000563
Treatment Summary:A 12-week randomized, double-blind, placebo controlled study will be conducted. After CTRC screening for inclusion/exclusion criteria, qualified subjects will be randomly assigned to 1 of 2 groups. The investigators involved in the acquisition and analysis of key outcomes will be blinded to the curcumin intake status of the subjects. With the assistance of dietary monitoring from the UC-Boulder CTRC bionutritionists, subjects will maintain their baseline diet with either unchanged (control) or enhanced curcumin intake delivered as capsules (Longvida®, Verdure Sciences): Group 1 = placebo (inert substances); Group 2 = curcumin (2000mg curcumin/day). Extensive published work has established that the curcumin dose of 2000 mg/day is well tolerated and safe. Sessions 1 & 2: Screening measurements. Session 3: Baseline measurements and blood draw. Sessions 4-8 (every other week to assess adherence and overall subject well-being): Body weight, BP, adherence, discuss any problems. Session 9: Identical to session 3 (stop intake of capsules after completion of post-testing).

Sample Preparation:

Sampleprep ID:SP000556
Sampleprep Summary:Venous blood sampling. All blood samples are handled in a similar time frame and immediately spun to extract plasma and stored in our -80 freezer until ready for analysis. acylcarnitine concentrations in plasma.

Combined analysis:

Analysis ID AN000805
Analysis type MS
Chromatography type Reversed phase
Chromatography system Waters Acquity
Column Waters Acquity BEH C8 (150 x 2mm,1.7um)
MS instrument type Triple quadrupole
MS instrument name Thermo Quantiva QQQ
Units uM


Chromatography ID:CH000580
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C8 (150 x 2mm,1.7um)
Chromatography Type:Reversed phase


MS ID:MS000712
Analysis ID:AN000805
Instrument Name:Thermo Quantiva QQQ
Instrument Type:Triple quadrupole